The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
Yesterday, the American Association for Cancer Research (AACR) joined the American Cancer Society (ACS), the American Society of Clinical...
As President of the American Association for Cancer Research (AACR), Michael A. Caligiuri, MD, is a strong advocate for...
Receiving a cancer diagnosis often means navigating numbers, such as estimates of the chance of recurrence. But cancer patients...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...
Three years ago, the American Association for Cancer Research (AACR) launched this blog with a welcome post from Chief...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today Nearly 1.7 million new cancer cases and roughly 600,000...
The American Association for Cancer Research (AACR) has appeared in numerous publications lately, showcasing the breadth of our mission...
recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib...
Prevention is often said to be more powerful than a cure. With an eye toward thwarting the disease, some...